{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:09:26Z","timestamp":1793772566819,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jgo.2021.06.011","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T08:27:51Z","timestamp":1624955271000},"page":"82-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)"],"prefix":"10.1016","volume":"13","author":[{"given":"Futa","family":"Koga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Nakashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ureshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Fukahori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Nio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Mitsugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2021.06.011_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jgo.2021.06.011_bb0010","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","author":"Ilic","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of Cancer in the older person: a practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2021.06.011_bb0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3748\/wjg.v22.i2.764","article-title":"Management of pancreatic cancer in the elderly","volume":"22","author":"Higuera","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0025","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju336","article-title":"Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802)","volume":"107","author":"Lamont","year":"2015","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2021.06.011_bb0035","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2021.06.011_bb0040","doi-asserted-by":"crossref","first-page":"dju413","DOI":"10.1093\/jnci\/dju413","article-title":"nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2021.06.011_bb0045","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10147-021-01859-2","article-title":"A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study","volume":"26","author":"Otsuka","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0050","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/ggi.13118","article-title":"Redefining the elderly as aged 75 years and older: proposal from the joint Committee of Japan Gerontological Society and the Japan geriatrics society: redefining elderly: proposal from Japan","volume":"17","author":"Ouchi","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.jgo.2021.06.011_bb0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2021.06.011_bb0060","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/S1470-2045(18)30098-6","article-title":"Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease","volume":"19","author":"ter Veer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","article-title":"Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients","volume":"82","author":"Bouillanne","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jgo.2021.06.011_bb0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.jgo.2021.06.011_bb0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/jjco\/hyy148","article-title":"Pancreas cancer incidence rates in the world from the Cancer incidence in five continents XI","volume":"48","author":"Okuyama","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0080","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s10147-019-01511-0","article-title":"A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer","volume":"24","author":"Hasegawa","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MPA.0000000000001484","article-title":"A multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer","volume":"49","author":"Kobayashi","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.jgo.2021.06.011_bb0090","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-019-03895-2","article-title":"The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients","volume":"84","author":"Ishimoto","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.2014-0202","article-title":"Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age","volume":"20","author":"Hurria","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2021.06.011_bb0100","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1186\/s12885-018-5101-3","article-title":"Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study","volume":"18","author":"Fern\u00e1ndez","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jgo.2021.06.011_bb0105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.21037\/jgo.2016.01.03","article-title":"Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial","volume":"7","author":"Scheithauer","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0110","doi-asserted-by":"crossref","DOI":"10.3892\/or.2018.6233","article-title":"Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death","author":"Passacantilli","year":"2018","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jgo.2021.06.011_bb0115","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab -paclitaxel is an active regimen in patients with advanced pancreatic Cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1253\/circj.CJ-12-1091","article-title":"Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction","volume":"77","author":"Kinugasa","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jgo.2021.06.011_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/4796598","article-title":"Geriatric nutritional risk index predicts adverse outcomes in human malignancy: a meta-analysis","volume":"2019","author":"Lv","year":"2019","journal-title":"Dis Markers"},{"key":"10.1016\/j.jgo.2021.06.011_bb0130","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/01635581.2013.804580","article-title":"Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome","volume":"65","author":"Bachmann","year":"2013","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.jgo.2021.06.011_bb0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0140","doi-asserted-by":"crossref","DOI":"10.4321\/S1130-01082010001100003","article-title":"Impact of preoperative levels of hemoglobin and albumin on the survival of pancreatic carcinoma","volume":"102","author":"Ruiz-Tovar","year":"2010","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.jgo.2021.06.011_bb0145","article-title":"Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT","volume":"1","author":"Alagappan","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jgo.2021.06.011_bb0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/CMAR.S229341","article-title":"The prognostic value of preoperative geriatric nutritional risk index in patients with pancreatic ductal adenocarcinoma","volume":"12","author":"Hu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jgo.2021.06.011_bb0155","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with Cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406821001594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406821001594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:55:00Z","timestamp":1761818100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406821001594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1879406821001594"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2021.06.011","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2021.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}